(Total Views: 910)
Posted On: 07/21/2020 10:05:28 PM
Post# of 155734
I haven’t seen any mention of the (apparent) fact that today’s report was not merely about safety.
If it were just a matter of safety (and assuming that placebos are, by definition, perfectly safe), then the placebo arm of the trial could not have had a significantly greater number of adverse events than the drug arm.
The claim that patients treated with Leronlimab suffered only about half as many adverse events is therefore already a strong statement about the efficacy of Leronlimab.
If this is correct, then I guess the question is what sort of adverse events Leronlimab kept these patients from experiencing — and whether they are potentially new indications.
If it were just a matter of safety (and assuming that placebos are, by definition, perfectly safe), then the placebo arm of the trial could not have had a significantly greater number of adverse events than the drug arm.
The claim that patients treated with Leronlimab suffered only about half as many adverse events is therefore already a strong statement about the efficacy of Leronlimab.
If this is correct, then I guess the question is what sort of adverse events Leronlimab kept these patients from experiencing — and whether they are potentially new indications.
(4)
(0)
